Brain Radiotherapy Combined with Targeted Therapy for HER2-Positive Breast Cancer Patients with Brain Metastases

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 1983;52(12):2349–2354. doi:10.1002/1097-0142(19831215)52:12<2349::AID-CNCR2820521231>3.0.CO;2-B
   PubMed Web of Science ®Google Scholar
• Tabouret E, Chinot O, Metellus P, Tallet A, Viens P, Goncalves A. Recent trends in epidemiology of brain metastases: an overview. Anticancer Res. 2012;32(11):4655–4662.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Kaufman PA, Huang W, et al. Quantitative measurement of HER2 expression in breast cancers: comparison with ‘real-world’ routine HER2 testing in a multicenter collaborative biomarker study and correlation with overall survival. Breast Cancer Res. 2015;17(1):41. doi:10.1186/s13058-015-0543-x
   PubMedGoogle Scholar
• Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006;17(6):935–944. doi:10.1093/annonc/mdl064
   PubMed Web of Science ®Google Scholar
• Cortes J, Dieras V, Ro J, et al. Afatinib alone or Afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, Phase 2 trial. Lancet Oncol. 2015;16(16):1700–1710. doi:10.1016/S1470-2045(15)00373-3
   PubMed Web of Science ®Google Scholar
• Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: american Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32(19):2100–2108.
   PubMed Web of Science ®Google Scholar
• Lin C, Wu J, Ding S, et al. Subdivision of M1 Stage for de novo metastatic breast cancer to better predict prognosis and response to primary tumor surgery. J Natl Compr Canc Netw. 2019;17(12):1521–1528. doi:10.6004/jnccn.2019.7332
   PubMedGoogle Scholar
• Xiao W, Li X, Yang A, et al. Analysis of prognostic factors affecting the brain metastases free survival and survival after brain metastases in breast cancer. Front Oncol. 2020;10:431. doi:10.3389/fonc.2020.00431
   PubMedGoogle Scholar
• Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97(12):2972–2977. doi:10.1002/cncr.11436
   PubMed Web of Science ®Google Scholar
• Shen Q, Sahin AA, Hess KR, et al. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. Oncologist. 2015;20(5):466–473. doi:10.1634/theoncologist.2014-0107
   PubMed Web of Science ®Google Scholar
• Eichler AF, Kuter I, Ryan P, Schapira L, Younger J, Henson JW. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer. 2008;112(11):2359–2367. doi:10.1002/cncr.23468
   PubMed Web of Science ®Google Scholar
• Church DN, Modgil R, Guglani S, et al. Extended survival in women with brain metastases from HER2 overexpressing breast cancer. Am J Clin Oncol. 2008;31(3):250–254. doi:10.1097/COC.0b013e31815a43c4
   PubMed Web of Science ®Google Scholar
• Kirsch DG, Ledezma CJ, Mathews CS, et al. Survival after brain metastases from breast cancer in the trastuzumab era. J Clin Oncol. 2005;23(9):2114–2116. doi:10.1200/JCO.2005.05.249
   PubMed Web of Science ®Google Scholar
• Soffietti R, Ahluwalia M, Lin N, Ruda R. Management of brain metastases according to molecular subtypes. Nat Rev Neurol. 2020;16(10):557–574. doi:10.1038/s41582-020-0391-x
   PubMed Web of Science ®Google Scholar
• Nabors LB, Portnow J, Ahluwalia M, et al. Central nervous system cancers, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(11):1537–1570. doi:10.6004/jnccn.2020.0052
   PubMed Web of Science ®Google Scholar
• Venur VA, Leone JP. Targeted therapies for brain metastases from breast cancer. Int J Mol Sci. 2016;17(9):1543. doi:10.3390/ijms17091543
   PubMed Web of Science ®Google Scholar
• Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, Phase 3 trial. Lancet Oncol. 2017;18(8):1049–1060. doi:10.1016/S1470-2045(17)30441-2
   PubMed Web of Science ®Google Scholar
• Brown PD, Jaeckle K, Ballman KV, et al. Effect of radiosurgery alone vs radiosurgery with whole brain radiotherapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA. 2016;316(4):401–409. doi:10.1001/jama.2016.9839
   PubMed Web of Science ®Google Scholar
• Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs. 2007;18(1):23–28. doi:10.1097/01.cad.0000236313.50833.ee
   PubMed Web of Science ®Google Scholar
• Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87(5):586–592. doi:10.1038/clpt.2010.12
   PubMed Web of Science ®Google Scholar
• Leone JP, Leone BA. Breast cancer brain metastases: the last frontier. Exp Hematol Oncol. 2015;4(1):33. doi:10.1186/s40164-015-0028-8
   PubMedGoogle Scholar
• Venur VA, Ahluwalia MS. Prognostic scores for brain metastasis patients: use in clinical practice and trial design. Chin Clin Oncol. 2015;4(2):18. doi:10.3978/j.issn.2304-3865.2015.06.01
   PubMedGoogle Scholar
• Subbiah IM, Lei X, Weinberg JS, et al. Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases. J Clin Oncol. 2015;33(20):2239–2245. doi:10.1200/JCO.2014.58.8517
   PubMed Web of Science ®Google Scholar
• Sperduto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419–425. doi:10.1200/JCO.2011.38.0527
   PubMed Web of Science ®Google Scholar
• Fares J, Kanojia D, Cordero A, et al. Current state of clinical trials in breast cancer brain metastases. Neurooncol Pract. 2019;6(5):392–401. doi:10.1093/nop/npz003
   PubMedGoogle Scholar
• Fares J, Kanojia D, Rashidi A, Ulasov I, Lesniak MS. Landscape of combination therapy trials in breast cancer brain metastasis. Int J Cancer. 2020;147(7):1939–1952. doi:10.1002/ijc.32937
   PubMedGoogle Scholar
• Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744–3752. doi:10.1200/JCO.2014.55.5730
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122–131. doi:10.1056/NEJMoa1703643
   PubMed Web of Science ®Google Scholar
• Gori S, Puglisi F, Moroso S, et al. The HERBA study: a retrospective multi-institutional Italian study on patients with brain metastases from HER2-positive breast cancer. Clin Breast Cancer. 2019;19(4):e501–e510. doi:10.1016/j.clbc.2019.05.006
   PubMedGoogle Scholar
• Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000;18(11):2349–2351. doi:10.1200/JCO.2000.18.11.2349
   PubMed Web of Science ®Google Scholar
• Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol. 2002;3(1):53–57. doi:10.1016/S1470-2045(01)00622-2
   PubMed Web of Science ®Google Scholar
• Kim JS, Kim K, Jung W, et al. New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12). Breast Cancer Res Treat. 2021;186(2):453–462. doi:10.1007/s10549-020-06043-0
   PubMedGoogle Scholar
• Yau T, Swanton C, Chua S, et al. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol. 2006;45(2):196–201. doi:10.1080/02841860500486630
   PubMed Web of Science ®Google Scholar
• Mahmoud-Ahmed AS, Suh JH, Lee SY, Crownover RL, Barnett GH. Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. Int J Radiat Oncol Biol Phys. 2002;54(3):810–817. doi:10.1016/S0360-3016(02)02967-X
   PubMed Web of Science ®Google Scholar
• Ou D, Cao L, Xu C, Kirova Y, Chen JY. Upfront brain radiotherapy may improve survival for unfavorable prognostic breast cancer brain metastasis patients with Breast-GPA 0-2.0. Breast J. 2019;25(6):1134–1142. doi:10.1111/tbj.13426
   PubMedGoogle Scholar
• Zhang Q, Chen J, Yu X, et al. Systemic treatment after whole-brain radiotherapy may improve survival in RPA class II/III breast cancer patients with brain metastasis. J Neurooncol. 2013;114(2):181–189. doi:10.1007/s11060-013-1169-4
   PubMedGoogle Scholar